Brief Pain Inventory Intensity Research Articles

Disease Phenotypes in Refractory Musculoskeletal Pain Syndromes Identified by Unsupervised Machine Learning.

Overlapping chronic pain syndromes, including fibromyalgia, are heterogeneous and often treatment-resistant entities carrying significant socioeconomic burdens. Individualized treatment approaches from both a somatic and psychological side are necessary to improve patient care. The objective of this study was to identify and visualize patient clusters in refractory musculoskeletal pain syndromes through an extensive set of clinical variables, including immunologic, psychosomatic, wearable, and sleep biomarkers. Data were collected during a multimodal pain program involving 202 patients. Seventy-eight percent of the patients fulfilled the criteria for fibromyalgia, 77% had a concomitant psychiatric-mediated disorder, and 22% a concomitant rheumatic immune-mediated disorder. Five patient phenotypes were identified by hierarchical agglomerative clustering as a form of unsupervised learning, and a predictive model for the Brief Pain Inventory (BPI) response was generated. Based on the clustering data, digital personas were created with DALL-E (OpenAI). The most relevant distinguishing factors among clusters were living alone, body mass index, peripheral joint pain, alexithymia, psychiatric comorbidity, childhood pain, neuroleptic or benzodiazepine medication, and response to virtual reality. Having an immune-mediated disorder was not discriminatory. Three of five clusters responded to the multimodal treatment in terms of pain (BPI intensity), one cluster responded in terms of functional improvement (BPI interference), and one cluster notably responded to the virtual reality intervention. The independent predictive model confirmed strong opioids, trazodone, neuroleptic treatment, and living alone as the most important negative predictive factors for reduced pain after the program. Our model identified and visualized clinically relevant chronic musculoskeletal pain subtypes and predicted their response to multimodal treatment. Such digital personas and avatars may play a future role in the design of personalized therapeutic modalities and clinical trials.

Validation and Psychometric Properties of the Spanish Version of King's Parkinson's Disease Pain Scale.

Objective: To assess the psychometric properties of the Spanish King's Parkinson's Disease Pain Scale (KPPS). Design: A descriptive transversal study at a Spanish hospital. Methods: Fifty-three Parkinson's disease (PD) patients suffering from otherwise explained pain (34 females, age = 63.42 ± 10.52 years, time with disease = 7.25 ± 4.65 years) were evaluated by the KPPS, Brief Pain Inventory (BPI), two Pain Pressure Thresholds (PPTs), Widespread Mechanical Hyperalgesia (WMH), and Conditioned Pain Modulation (CPM). A retest of the KPPS was performed 7-15 days later. Internal consistency, test-retest reliability (intraclass correlation coefficient (ICC)), measurement error, factor structure, and criterion/convergent validity were assessed. Results: Internal consistency of the Spanish KPPS was acceptable (Cronbach's alpha = 0.77). The mean test and retest total KPPS scores were similar (test = 34.83 ± 23.50 points, retest = 35.87 ± 26.23 points), and test-retest reliability was good (ICC = 0.85, 95% CI = 0.75-0.91). Standard error of measurement (SEM) was 9.1 points and smallest detectable change (SDC) was 25.22 points. The sampling adequacy was not sufficient to perform factor analysis. The total KPPS score was not correlated to the BPI intensity subscale (r = 0.18, p=0.19), but it was moderately and positively correlated to the interference subscale (r = 0.43, p=0.001). The total KPPS was moderately and negatively correlated to both the remote PPT (r = -0.4, p=0.003) and WMH (r = -0.38, p=0.005). No statistical correlations were found with local PPT or CPM. Conclusion: The present study provides evidence that the Spanish KPPS effectively measures pain in individuals with PD, with its total score demonstrating good reliability, minimal measurement error, and adequate criterion and convergent validity.

Abstract P4-08-01: Effectiveness of electroacupuncture versus auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: The PEACE randomized clinical trial

Abstract Introduction: Chronic musculoskeletal pain is common and debilitating among breast cancer survivors. Recently, the Personalized Electroacupuncture (EA) versus Auricular Acupuncture (AA) Comparative Effectiveness (PEACE) trial demonstrated that both acupuncture methods improved pain control better than usual care (UC) in cancer survivors. However, the comparative effectiveness between EA and AA among breast cancer survivors, specifically, for chronic musculoskeletal pain is unknown. Here, we report the results of breast cancer survivors enrolled in the PEACE trial. Methods: PEACE is a three-arm, parallel, single center randomized trial investigating the effectiveness of EA and AA versus UC for chronic musculoskeletal pain in 360 cancer survivors. Patients in both EA and AA received ten weekly treatments. Patients in UC could receive ten EA treatments after week 12. The primary endpoint was the change in mean Brief Pain Inventory (BPI) pain intensity from baseline to week 12; change from baseline to week 24 was a secondary endpoint. We analyzed the subset of trial participants with a primary diagnosis of breast cancer (46%). We conducted constrained linear mixed model analyses, which constrained all arms to have a common pre-randomization baseline mean. Model-based mean estimates at weeks 12 and 24 were compared between arms using model contrasts. Results: Among the 165 breast cancer survivors, mean (SD) age was 60.3 (11.0) years, 35.8% were non-white, and mean time since cancer diagnosis was 5.4 (6.5) years. Patients had been experiencing pain for 5.6 (7.3) years, with baseline mean pain severity of 5.35 (95% CI: 5.04, 5.66). 86.7% had a prior history of surgery, 43.0% chemotherapy, 64.8% radiotherapy, and 50.3% endocrine therapy. The common locations of pain were lower back (24.2%), knee/leg (23.6%), and shoulder/arm/elbow (13.9%). 107 (66.9%) patients were taking pain medication. At week 12, the BPI pain severity score was 2.69 (2.26. 3.13) in EA, 3.60 (3.17, 4.02) in AA, and 5.06 (4.47, 5.65) in UC. The change in mean BPI intensity score from baseline was -2.65 (-3.06, -2.25), -1.75 (-2.15, -1.35), and -0.29 (-0.86, 0.28) in EA, AA, and UC, respectively (Table 1). At week 24, the mean BPI pain severity was 2.84 (95% Confidence Interval [CI]: 2.40, 3.28) in EA and 3.67 (95% CI: 3.23, 4.10) in AA. EA reduced pain severity significantly more than AA at both week 12, (-0.90 [-1.45, -0.36], p =0.001) and week 24 (-0.82, [-1.38, -0.27], p=0.004). Minimal toxicities were reported. Conclusions: While both EA and AA were associated with clinically meaningful and persistent reduction of pain among breast cancer survivors, EA was more effective than AA at reducing pain severity. Breast cancer survivors with chronic musculoskeletal pain may consider EA. Table 1.Changes in BPI Pain Intensity from BaselineBPI Pain IntensityUCEAAAEA vs AAChange from baselineChange from baselineDifference from UCChange from baselineDifference from UCDifference between EA and AAWeek 12Mean (95% CI)-0.29 (-0.86, 0.28)-2.65* (-3.06, -2.25)-2.37*(-3.05, -1.68)-1.75* (-2.15, -1.35)-1.46* (-2.14, -0.78)-0.90* (-1.45, -0.36)*p≤0.001 Citation Format: Wanqing Iris Zhi, Jun J Mao, Raymond E Baser, Susan Q Li, Vicotria S Blinder, Larry Norton, Andrew D Seidman, Mark E Robson, Ting Bao. Effectiveness of electroacupuncture versus auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: The PEACE randomized clinical trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-08-01.

Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.

Pain is a common and disabling non-motor symptom (NMS) of Parkinson's disease (PD), which occurs through the course of the disease, often unrecognized and undertreated. For this study, we evaluated the efficacy and safety of safinamide to reduce pain in PD patients with motor fluctuations. A total of 13 PD patients with pain receiving safinamide (Xadago®, 100mg/daily) were prospectively evaluated for 12weeks. The primary outcome measures were changes in the total score of the King's Pain Scale for Parkinson's Disease (KPPS), Brief Pain Inventory (BPI) Intensity and Interference, and the Numeric Rating Scale (NRS). Secondary outcomes were the proportion of pain responders, changes in the Clinical Global Impression of Change (CGI), the Parkinson's disease Quality of Life 39 (PDQ39), the Unified Parkinson's Disease Rating Scale parts III and IV (UPDRS III and IV), and laser-evoked potentials (LEPs). LEPs were used to assess potential changes in the central processing of nociceptive inputs. The safety profile was evaluated based on the occurrence of treatment-emergent side effects and the dropout rate. After 12weeks of add-on safinamide therapy, a significant improvement was noted in the primary (KPPS, BPI Intensity and interference, and NRS) and the secondary outcomes (UPDRS III, IV, CGI, and PDQ39). No significant changes in LEP complexes were observed. All patients completed the study and no treatment-emergent side effects were reported. Our preliminary findings suggest that safinamide 100mg/day may be effective for the management of pain in PD patients with motor fluctuations and is safe. Further randomized controlled trials are needed to confirm its efficacy.

Pain Characteristics and Their Relationship With Motor Dysfunction in Individuals With Parkinson Disease-A Cross-Sectional Study.

Pain is a common symptom in Parkinson disease (PD). To analyze the relationship between pain and motor dysfunction in individuals with PD. Fifty-four individuals with PD were screened: Hoehn and Yahrscale score =2.5 (1 to 4); median (range) age in the "on" period of anti-Parkinson medication was 66 (44 to 85) years. Pain was assessed using King's Parkinson's Disease Pain Scale (KPPS) and the Brief Pain Inventory (BPI). Performance in routine activities and motor function were assessed using Unified Parkinson Disease Rating Scale (UPDRS II and III); gait was assessed using the Dynamic Gait Index; and balance was assessed using the Mini-BESTest. Thirty-eight participants (70.3%) reported mild to moderate pain. A positive correlation was found between the total KPPS score and performance in general activities (UPDRS II) (rho=0.29, P=0.04); a negative correlation was found between pain intensity (BPI intensity) and motor function (UPDRS III; rho=-0.28, P=0.04); and a negative correlation was found between pain intensity (BPI intensity) and the bradykinesia subscore of the UPDRS III (rho=-0.29, P=0.04). There was no correlation between pain and gait performance or balance. The musculoskeletal pain was the predominant type (in 81.5% of subjects), followed by nocturnal pain (52.6%) and fluctuation-related pain (47.3%). The most painful areas were lower limbs (33.0%) and shoulders/cervical area (31.0%). Twenty-one of 38 participants (55.3%) reported pain interference in their working and walking ability and general activities. Pain was weakly correlated with performance in general activities and with bradykinesia but was not correlated with the remaining classic motor PD symptoms, either gait or balance performance. Pain was a prevalent symptom in the present sample, and the individuals reported its interference with functionality.

Sleep disorders in patients with chronic stroke: A cross-sectional study

Sleep disruption is a common disorder (about 50%) in patients after stroke, resulting in reduction in sleep time due to the increased number of awakens. It has already been described that sleep architecture is modified in stroke patients: time spent in non-rapid eye movement-1 (NREM1) phase is increased, while rapid eye movement (REM) and non-rapid eye movement-3 (NREM3) phases are reduced. The aim of this cross-sectional study was to investigate the mechanisms of sleep alterations and the correlation with the impact of the cerebrovascular accident on health and quality of life in patients with chronic stroke We included patients aged ≥ 18 years with a diagnosis of chronic stroke (≥ 12 months from acute event). Patients with Sleep Breathing Disorders (SBD) or presenting other major comorbidities were excluded. We assessed: stroke severity, using the Stroke Impact Scale (SIS); depression, by Hamilton Depression Rating Scale (HAM-D); pain using the Brief Pain Inventory (BPI); sleep perception by Pittsburgh Sleep Quality Index (PSQI). Sleep architecture was assessed by X4 Sleep Profiler™ In-Home EEG Sleep Monitor–Advanced ® , an in-home multi-night sleep monitoring device. We enrolled 9 patients, mean aged 71.11 ± 12.64 years, with a mean HAM-D = 15.11 ± 6.90, a mean BPI intensity index = 3.75 ± 1.51 and mean BPI interference index = 6.21 ± 2.82. Sleep was perceived as poor, with a global PSQI of 10.00 ± 4.66. We found a reduction of time spent in NREM3 phase and an increased time spent in NREM1 and NREM2 with an increased number of awakens and cortical arousals in accordance with the literature. Moreover, time spent in NREM3 phase was significantly correlated to SIS mobility ( r = 0.861; P = 0.003) and SIS hand function ( r = 0.707; P = 0.030). This cross-sectional study suggests a correlation between sleep alteration and the functioning of stroke patients, although prospective trials are necessary to better clarify this finding.